British Business Bank has committed €25 million to EQT Life Sciences’ Health Economics 3 fund, extending its support for European medical technology and digital health companies seeking commercial growth capital.
The fund will invest in businesses developing medical devices, diagnostics, health technology, and digitally enabled care systems. Its focus is expected to fall on companies that have passed much of the early technical risk but still require capital to expand manufacturing, complete regulatory work, enter new markets, or build commercial operations.
EQT Life Sciences has raised more than €3.7 billion across 13 funds during a 30-year investment history and has supported more than 150 companies. Its Health Economics strategy combines conventional life sciences investment with an assessment of whether technologies can improve clinical outcomes while reducing or controlling healthcare costs.
British Business Bank participation forms part of a wider effort to attract international institutional capital into UK growth companies. Although Health Economics 3 will invest across Europe, its UK activity is expected to provide domestic businesses with access to specialist investors, commercial expertise, and international networks.
Previous co-investments linked to the strategy include Phagenesis, which raised a $42 million Series D round in 2023, and Cyted Health, which completed a $44 million Series B round in 2025. Both companies illustrate the size of funding often needed to move regulated medical technologies from technical development towards broader clinical and commercial deployment.
Life sciences remains a priority sector within the UK Industrial Strategy, combining research strength with advanced manufacturing and high-value exports. Many companies, however, encounter a difficult transition between successful trials or regulatory approval and sustained production at commercial scale.
Scale-up capital must reach manufacturing
Medical technology companies frequently require more capital than conventional software businesses because growth depends on physical production, validated supply chains, clinical evidence, quality systems, and regulatory compliance. A device may perform successfully in trials while remaining several years away from economical, repeatable manufacturing.
Production equipment must be selected and qualified, suppliers need to meet traceability requirements, and manufacturing processes must demonstrate consistent performance across larger volumes. Changes to materials, components, or assembly methods can trigger further validation, limiting the speed at which costs can be reduced after launch.
Diagnostics businesses face similar demands because reagents, consumables, instruments, packaging, software, and data systems must operate as an integrated product. Manufacturing environments need sufficient controls to maintain repeatability while batch volumes increase and distribution expands.
Digital health companies carry less physical infrastructure, but clinical governance, cybersecurity, interoperability, and procurement remain substantial barriers. Selling into healthcare systems can involve long evaluation cycles, fragmented decision-making, and complex routes through hospitals, commissioners, and national bodies.
Specialist investors can influence manufacturing strategy as well as company ownership, helping management teams plan regulatory pathways, recruit experienced operations leaders, select contract manufacturers, and avoid expansion decisions that create costly revalidation work.
The UK has repeatedly struggled to retain the full economic value generated by domestic life sciences research. Intellectual property and early clinical evidence may be established in Britain before larger funding rounds, commercial teams, or manufacturing programmes move overseas.
Capital alone cannot resolve the problem because commercial adoption remains equally important. Calls for reform of medical technology procurement have highlighted the difficulty of introducing proven devices into systems where purchasing routes remain inconsistent or focused heavily on initial price.
A health economics approach attempts to address part of that constraint by assessing whether a technology can demonstrate measurable value to healthcare providers. Devices that reduce hospital stays, avoid complications, improve diagnosis, or shift treatment into lower-cost settings may present a stronger commercial case even where their unit price is higher.
Manufacturers must therefore produce economic evidence alongside technical and clinical data, adding another demanding workstream to product development. Procurement teams and clinical decision-makers need results that can be applied to real service settings rather than general claims of efficiency.
The fund’s European scope may help portfolio companies enter several healthcare markets, although reimbursement, procurement, and regulatory practices still vary considerably between countries. Commercial expansion requires local knowledge and cannot be managed as a single regional launch.
The €25 million commitment increases the pool of specialist capital available to British and European medical technology companies at the scale-up stage. Its industrial return will be measured through qualified production lines, larger technical workforces, export growth, and technologies that progress beyond approval into routine clinical use.
